金融界4月30日消息，安琪酵母下周将迎来276.5万股解禁，解禁市值约9848.93万元，占解禁前流通市值 比例为0.32%。 安琪酵母所属概念板块包括：食品饮料、湖北板块、标准普尔、富时罗素、MSCI中国、沪股通、中证 500、上证180_、参股新三板、融资融券、QFII重仓、合成生物、化妆品概念、长寿药、湖北自贸、央 国企改革。 资料显示，安琪酵母股份有限公司位于湖北省宜昌市城东大道168号，公司始创于1986年,主导产品酵母 及深加工产品经过30多年的开发,已被广泛应用于烘焙与发酵面食、食品调味、酿造、人类营养健康、 动物、植物、微生物营养等领域。公司在国内11个城市以及埃及、俄罗斯建有工厂,发酵总产能达40万 吨,在国内市场占比55%,在全球占比超18%,酵母系列产品规模已居全球第二。公司建有国家级企业技术 中心、博士后科研工作站,检测中心通过CNAS实验室认可,获得授权发明专利300余项。主导和参与制定 了酵母行业所有的国家和行业标准,两次获得国家科技进步奖。近年来,先后被工信部评为"国家技术创新 示范企业",被国务院国资委评为"国有重点企业管理标杆创建行动标杆企业""创建世界一流专业领军示 范企业 ...

智通财经4月29日电，《海南省全面深化药品医疗器械化妆品监管改革促进医药产业高质量发展实施方 案》29日对外发布。其中提出，助力实现化妆品产业异军突起。一是支持化妆品新原料和化妆品新品研 发。鼓励高校、科研单位和企业聚焦珍珠、椰子、沉香、芦荟、海藻等海南特色动植物资源，加大产学 研合作力度，加速推进科技成果转化。对完成特殊化妆品注册、化妆品新原料注册或备案并在海南落地 生产，符合条件的给予一定的资金支持。二是提升产业竞争力。支持企业优化化妆品生产工艺、完善原 料标准和安全评估体系，打造海南特色化妆品及原料品牌，增强核心竞争力。 海南：支持企业优化化妆品生产工艺 打造海南特色化妆品及原料品牌 ...

Core Viewpoint - The company, Qing Song Co., Ltd., is primarily engaged in the design, research and development, and manufacturing of cosmetics, including facial masks, skincare products, and wet wipes, with a significant focus on ODM (Original Design Manufacturer) services [6][8]. Company Overview - The company operates in the chemical raw materials and chemical products manufacturing industry, specifically in the cosmetics manufacturing sector [6]. - The main business entity is its wholly-owned subsidiary, Nuo Si Bei Cosmetics Co., Ltd., which contributes 99.52% of the consolidated revenue [8]. Business Operations - Nuo Si Bei specializes in the design, research and development, and manufacturing of facial masks, skincare products, wet wipes, and non-woven fabric products, making it one of the largest domestic ODM companies in China [8]. - The upstream supply chain includes natural cellulose fibers, polyester fibers, and viscose fibers for mask substrates, while the downstream market consists of cosmetic brand owners and various retail channels, including e-commerce and physical stores [9]. Financial Data - The company has not restated or adjusted previous years' financial data, indicating stability in its financial reporting [10]. - The company has implemented a share repurchase plan, with a total repurchase amount of approximately RMB 65.8 million, representing 3.49% of the total share capital [11]. Major Projects - The company has decided to terminate the construction of a large industrial park project on 148 acres and is negotiating with government authorities to return the land use rights [12][13]. - A new investment partnership has been formed with Mi Jia Technology Co., Ltd. to develop the 148-acre land project, with Nuo Si Bei holding a 20% stake in the newly established joint venture [13][14]. Strategic Investments - The company has increased its stake in Guangdong Ke Pu Rui Biotechnology Co., Ltd. to 60%, enhancing its capabilities in synthetic biology and new material technology [15]. - A new wholly-owned subsidiary, Guangdong Nuo Mi Jia Biomedical Co., Ltd., has been established to support the company's strategic development needs [16].

Investment Rating - The investment rating for the company is upgraded to "Accumulate" [1] Core Views - The company's short-term performance is under pressure due to factors such as inventory adjustments and price changes, but there is optimism for long-term growth driven by new product launches [1][8] - The company is a leading global player in cosmetic raw materials, and while 2024's performance is affected by the downstream inventory cycle, the increasing penetration of new sunscreen agents is a long-term industry trend [8] - The company has sufficient capacity reserves and is actively expanding production, particularly in Malaysia, which will enhance its risk resistance and international presence [8] Financial Summary - Total revenue for 2024 is projected at 22.76 billion yuan, a decrease of 5.16% year-on-year, with a net profit of 5.62 billion yuan, down 23.33% [8] - The gross margin for 2024 is expected to be 44.40%, while the net profit margin is projected at 24.65% [8] - The company's earnings per share (EPS) for 2024 is estimated at 1.66 yuan, with a price-to-earnings (P/E) ratio of 12.61 [1][9]

Core Viewpoint - The National Medical Products Administration (NMPA) of China announced that 30 batches of cosmetics failed to meet regulatory standards, involving well-known brands such as Fanwenhua, Tianqi, SKINO, and others, due to issues like illegal ingredient additions and microbial contamination [1][2]. Group 1: Non-compliance Issues - A total of 30 batches of cosmetics were reported for non-compliance, including issues such as illegal ingredient additions, excessive total bacterial counts, and high levels of mold and yeast [1][2]. - Specific products from Tianqi, including Tianqi Pa Shang Huo toothpaste, showed bacterial counts of 640,000 CFU/g and 19,000 CFU/g, exceeding the standard limit of 500 CFU/g by 1280 times [2]. - Fanwenhua's products, including the whitening essence cream and water light essence, were found to contain unlisted whitening agents, violating regulations that require product labels to match registered information [2]. Group 2: Regulatory Actions - The NMPA has mandated local drug regulatory authorities in regions such as Tianjin, Shanghai, Jiangsu, Zhejiang, Shandong, Guangdong, and Guangxi to conduct investigations and take corrective actions against the companies involved [2]. - Companies are required to immediately cease operations related to the non-compliant products and undertake necessary investigations and rectifications [2].

证券代码：301076 证券简称：新瀚新材 公告编号：2025-008 一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 天健会计师事务所（特殊普通合伙）对本年度公司财务报告的审计意见为：标准的无保留意见。 本报告期会计师事务所变更情况：公司本年度会计师事务所由变更为天健会计师事务所（特殊普通合 伙）。 非标准审计意见提示 □适用 √不适用 公司上市时未盈利且目前未实现盈利 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 公司经本次董事会审议通过的利润分配预案为：以134,524,000为基数，向全体股东每10股派发现金红利 1.00元（含税），送红股0股（含税），以资本公积金向全体股东每10股转增3股。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 1、公司简介 ■ 2、报告期主要业务或产品简介 公司主营业务为芳香族酮类产品的研发、生产和销售，主要产品包括特种工程塑料核心原料、光引发剂 和化妆 ...

21日，国家药监局发布 《关于30批次不符合规定化妆品的通告》 。 通告显示，2024年国家化妆品抽样检验中，经山东省食品药品检验研究院等单位检验，产品标签标示名称为北芙美白沐浴露等30批次化妆品不符合规定。 根据《化妆品监督管理条例》《化妆品生产经营监督管理办法》《化妆品抽样检验管理办法》，国家药品监督管理局要求天津、上海、江苏、浙江、山 东、广东、广西等省（区、市）药品监督管理部门对上述不符合规定化妆品涉及的注册人、备案人、受托生产企业等依法立案调查， 责令相关企业立即 依法采取风险控制措施并开展自查整改 。 各省（区、市）药品监督管理部门要 责令相关化妆品经营者立即停止经营上述化妆品 ，并依法调查其进货查验记录等情况，对违法产品进行追根溯源， 发现违法行为的，依法严肃查处；涉嫌犯罪的，依法移送公安机关。 往期推荐 | 序号 | 标示产品 名称 | 标示化妆 品注册人 备案人、受 | 标示化妆品注 册人/备案人、 受托生产企 | 被抽样单 | 被抽班单位 | 包装 | 标示 | 标示 | 标示限 期使用 | 标示化妆 昌注册人/ 备案人、受 托生产企 | 特殊化妆 品注册证 | 标示生 | 检验机 | 不 ...

Group 1 - The chairman and CEO of the company, Dr. Tong Youzhi, increased his stake in the company by purchasing 200,000 shares for HKD 259,000 at an average price of HKD 1.295 per share, representing approximately 0.0447% of the total issued share capital as of the announcement date [1] - Dr. Tong exercised rights to 1.25 million restricted stock units, corresponding to 1.25 million ordinary shares, which vested on March 31, 2025 [1] - Following this acquisition, Dr. Tong holds a total of 49.2003 million shares, representing about 10.99% of the total issued share capital as of the announcement date [1] Group 2 - The increase in shareholding demonstrates Dr. Tong's strong confidence in the company's commercialization prospects and growth potential, as well as recognition of its long-term investment value [2] - The company plans to continue focusing on the dermatology field, enhancing existing cosmetic products, broadening product coverage, and accelerating the launch of new cosmetic products to enrich its product matrix [2] - The company is actively exploring the market potential for effective raw materials, specifically KT-939 and KX-826, and is seeking collaboration opportunities with cosmetic brand owners to expand its raw material business and cultivate new profit growth points [2]

Core Viewpoint - The report from CITIC Securities indicates that the development of the Japanese cosmetics industry over the past century has been closely linked to economic growth and changing consumer demand, highlighting structural opportunities in the market post-1980s [1] Group 1: Economic and Demand Evolution - Before the 1980s, the Japanese cosmetics industry experienced high economic growth and industry expansion [1] - After the 1980s, the industry saw a slowdown, with demand characteristics giving rise to structural opportunities [1] Group 2: Product and Pricing Trends - There is a differentiation in product pricing, with stable high-end demand and an increase in cost-performance products driven by the demand for effective cosmetics [1] - The evolution of distribution channels is influenced by cost-performance, with drugstores leveraging low prices to gain market share [1] Group 3: Market Comparison between Japan and China - The current market environment in China shows similarities to Japan's post-1980s, with a stable growth phase and consumer preferences reflecting cost-performance and effective skincare [1] - However, there are significant differences in market structure, with foreign brands dominating the top market in Japan, while domestic brands in China are better aligned with current consumer demands for quality and price-performance [1]

证券简称：芭薇股份 证券代码：837023 广东芭薇生物科技股份有限公司 广东省广州市白云区新贝路 5 号 广东芭薇生物科技股份有限公司招股说明书（申报稿） 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行 股票的法律效力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证 券交易所主要服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风 险高等特点，投资者面临较大的市场风险。投资者应充分了解北京证券交易所市场的 投资风险及本公司所披露的风险因素，审慎作出投资决定。 保荐机构（主承销商） （广州市天河区珠江东路 11 号 18、19 楼全层） 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对 注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行 人的盈利能力、投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相 反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由发行人 自行负责；投资者自主判断发行人的投资价值 ...